Credit: Shutterstock. Study participants suffered from chronic back pain for an average of 12.8 years. The Food and Drug Administration (FDA) has expanded the approval of Abbott’s spinal cord ...

Please provide your email address to receive an email when new articles are posted on . Abbott has announced the FDA expanded the indication of its BurstDR spinal cord stimulation devices for treating ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The US Food and Drug Administration (FDA) has approved expanded MRI labeling for Abbott Laboratories' Eterna spinal cord stimulation (SCS) system, which will allow for higher-quality scan images for ...

Abbott has touted the potential of its neuromodulation portfolio in reducing patient and healthcare burdens associated with chronic pain following the positive results of three five-year analyses. The ...

Among the first 200 participants in a trial of its spinal cord stimulation systems, about 85% of those who were implanted with the Proclaim XR system achieved “significant back pain reduction,” ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...

Abbott ABT recently announced the first usage of its Eterna spinal cord stimulator (SCS) system in Canada. This marks a significant milestone in the company’s approach to chronic pain management. The ...